SCODiA Report by MLBI Lab

Single-Cell Transcriptomics Reveals Malignant Intercalated Cell Reprogramming and Immune Dysfunction in Kidney Cancer

Single-cell RNA sequencing of kidney tissue reveals profound molecular and cellular reprogramming in tumor versus normal conditions. Intercalated cells, identified as a tumor-origin cell type, exhibit widespread aneuploidy with recurrent amplifications, notably of EGFR, and activate key oncogenic pathways like PI3K-Akt, MAPK, ErbB, and VEGF signaling. These tumor-associated Intercalated cells also upregulate immune checkpoint molecules such as PD-L1 and HLA Class II, suggesting active immune evasion. The tumor microenvironment (TME) is characterized by significant immune dysregulation: an expansion of immunosuppressive regulatory T cells (Tregs) and pro-tumorigenic M2C/M2D macrophage subsets, a concomitant decrease in anti-tumor NK cells, and evidence of T cell exhaustion (impaired T cell receptor signaling, elevated PD-1/PD-L1). Extensive cell-cell interaction analysis highlights dominant pro-tumorigenic crosstalk involving EGFR, VEGFA-VEGFR, SPP1-integrin, and CXCL12-CXCR4 pathways, driving angiogenesis, extracellular matrix (ECM) remodeling, and further immune evasion.

Contents

  1. Dataset overview
  2. UMAP Visualization of Kidney scRNA-seq Data by Condition, Sample, Cell Type, and Ploidy
  3. UMAP Visualization of Key Marker Gene Expression and Minor Cell Type Annotations
  4. Celltype Subtype Marker Expression Analysis
  5. Genomic Copy Number Alterations in Tumor-Origin and Unassigned Kidney Cells
  6. CNV-driven UMAP Embedding of Kidney Single-Cell RNA-seq Data
  7. Kidney Cell Type Population Changes in Tumor vs. Normal Conditions
  8. T 세포 하위 집단 분석: 신장 종양 미세환경 내 면역 세포 조성 변화
  9. Macrophage Subset Population Analysis in Normal vs. Tumor Kidney Tissue
  10. Changes in T Cell Subset Proportions in Kidney Tumor Microenvironment
  11. Differential Macrophage Subset Proportions in Kidney Tumor vs. Normal Tissue
  12. Cell-Cell Interaction Patterns in the Kidney Tumor Microenvironment
  13. Differential Cell-Cell Interaction Analysis in Normal vs. Tumor Kidney Conditions
  14. Immune Checkpoint and Cell Cycle Pathway Interactions in Kidney Tumor Microenvironment
  15. Condition-Specific Cell-Cell Interaction Patterns in Kidney Tissue
  16. Condition-Specific Surfaceome Markers of Intercalated Cells in Kidney Tissue
  17. Macrophage Condition-Specific Surfaceome Markers in Kidney Tissue
  18. T cell CD4+ Condition-Specific Surfaceome Markers in Kidney Tissue
  19. Gene Ontology (GSA) Analysis of Intercalated Cells in Kidney Tissue
  20. Intercalated cell, Macrophage, and T cell CD4+ Gene Set Enrichment Analysis in Kidney Tumor Microenvironment
  21. Discussion
  22. Query List

0. Dataset overview

Dataset Summary

Cell Type Annotations: Cells are annotated at multiple hierarchical levels

1. UMAP Visualization of Kidney scRNA-seq Data by Condition, Sample, Cell Type, and Ploidy

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP visualizations of single-cell RNA sequencing data from kidney tissue, colored by various experimental and biological annotations: condition (normal vs. tumor), sample, celltype_major, celltype_minor, celltype_subset, and ploidy_dec (aneuploidy status). These plots offer a comprehensive overview of the dataset's structure, revealing how different factors contribute to cellular heterogeneity and organization in the embedding space.

Visual Summary

Condition

The UMAP plot colored by condition shows a clear separation between cells originating from "normal" (maroon) and "tumor" (dark blue) kidney tissues. A significant proportion of cells from tumor samples cluster distinctly, forming several large, interconnected groups, while "normal" cells mostly occupy separate regions. However, there are also areas where normal and tumor cells appear to intermix, which could represent shared cell populations (e.g., immune cells infiltrating the tumor) or normal kidney cells within the tumor microenvironment.

Sample

The sample plot, displaying 15 individual samples, generally indicates a good mixing of cells from different samples within many of the UMAP clusters. This suggests that the primary clustering is driven by biological differences rather than strong batch effects. However, some clusters show a dominance of cells from specific samples, particularly within the larger "tumor" regions, which could reflect inter-patient tumor heterogeneity or unique cellular compositions within certain individuals. For instance, the large cluster on the bottom-right and the upper-middle cluster show strong sample-specific enrichment.

Cell Type Annotations (Major, Minor, Subset)

The celltype_major, celltype_minor, and celltype_subset plots reveal that the UMAP structure largely corresponds to distinct cell identities, confirming the biological relevance of the embedding.

Ploidy Status (ploidy_dec)

The ploidy_dec plot shows a strong association between aneuploidy and specific UMAP clusters. Cells labeled "Aneuploid" (maroon) predominantly co-localize with the large clusters previously identified as "tumor" cells in the condition plot. Conversely, "Diploid" cells (light yellow) are largely found in regions corresponding to "normal" kidney tissue and potentially normal immune/stromal cells within the tumor microenvironment. A subset of cells with "Unclear" ploidy (dark blue) are also present, often intermixed or forming small distinct groups.

Biological Interpretation

The UMAP visualizations provide critical biological insights into the kidney single-cell dataset:

  1. Clear Separation of Tumor vs. Normal Microenvironments: The distinct clustering of "tumor" and "normal" cells in the condition plot, strongly corroborated by ploidy_dec, indicates successful capture of disease-specific cellular states. The primary tumor clusters are almost exclusively "Aneuploid," which is a hallmark of cancer cells due to chromosomal instability. GeneCards, "Aneuploidy in Cancer"
  2. Cell Type Heterogeneity in Kidney and Tumor: The progressive refinement of cell type annotations from celltype_major to celltype_subset reveals the rich cellular diversity within the kidney. Importantly, both resident kidney cells (e.g., Proximal Tubule, Podocyte, Intercalated cell) and immune/stromal components are well-represented and distinguishable.
  3. Identification of Tumor Cells and Origin: The data context states "Tumor origin celltype: unassigned, Intercalated cell." Observing the celltype_major/minor plots, the Intercalated cell (IC) population overlaps significantly with some of the Aneuploid/Tumor clusters. This supports the hypothesis that Intercalated cells could be a cell of origin for this kidney tumor type or contribute substantially to the tumor mass. The large "unassigned" cluster in the celltype_major and celltype_minor plots, which largely overlaps with "Aneuploid" and "tumor" cells, further suggests these might be highly aberrant tumor cells that have lost their original lineage markers or represent cells of an unknown origin transformed into tumor cells.
  4. Tumor Microenvironment (TME) Composition: The presence of immune cells (T cells, Myeloid cells, B cells) and stromal cells (Fibroblast, Smooth muscle cells, Endothelial cells) within the tumor clusters suggests the successful capture of components of the tumor microenvironment. Sub-categorization in celltype_subset (e.g., various Macrophage and T cell subsets) allows for detailed investigation of immune cell polarization and activation states within the TME, which is crucial for understanding anti-tumor immunity and therapeutic responses.
  5. Quality of Embedding and Annotation: The concordance between genetic features (implied by UMAP clustering), sample origin, cell type annotations, and ploidy status suggests a high-quality embedding that accurately reflects underlying biological differences. The annotations are consistent and provide increasingly granular resolution of cell identity.

Annotation Notes

2. UMAP Visualization of Key Marker Gene Expression and Minor Cell Type Annotations

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the expression of a panel of known cell type-specific marker genes on a Uniform Manifold Approximation and Projection (UMAP) plot, alongside the pre-computed celltype_minor annotations. The goal is to assess the consistency and distinctness of the identified cell populations based on canonical gene markers, providing a crucial step in validating cell type assignments in the kidney single-cell RNA-seq dataset.

Visual Summary

The UMAP plots display 26,502 cells, colored by expression level for individual genes and by their assigned celltype_minor label. The embedding shows a diverse landscape of distinct clusters, reflecting the cellular heterogeneity of the kidney tissue.

T Cell Markers (CD3D, CD4, CD8A):

B Cell / Plasma Cell Markers (CD79A, MS4A1, MZB1):

Myeloid Cell Markers (CD14, LYZ):

Stromal / Endothelial / Epithelial Markers (FBLN1, NOTCH3, EPCAM, MUC1, CD34):

The final celltype_minor UMAP plot visually integrates all these annotations, showing distinct, well-separated clusters for most cell types. 'Unassigned' cells form several smaller, less cohesive clusters or are sparsely distributed.

Biological Interpretation

The UMAP visualization of marker gene expression provides strong evidence for the accurate annotation of major and minor cell types within the kidney scRNA-seq dataset.

  1. Robust Immune Cell Identification: The clear, specific expression of CD3D, CD4, CD8A, CD79A, MS4A1, MZB1, CD14, and LYZ in their expected immune cell clusters (T cells, B cells, Plasma cells, Macrophages/DCs) confirms the robust identification and delineation of these immune populations. This is particularly important for understanding the immune microenvironment in both tumor and normal kidney conditions. The ability to distinguish T cell subsets (CD4+ vs CD8+) and B cells from plasma cells using specific markers indicates high resolution in annotation.
  2. Kidney Parenchymal Cell Integrity: The expression patterns of EPCAM and MUC1 in kidney-specific epithelial cells like Proximal Tubule, Thick Ascending Limb, Intercalated cells, and Podocytes validate these annotations. This ensures that the primary functional units of the kidney are correctly identified, which is crucial for studying kidney function and disease pathology.
  3. Stromal and Endothelial Cell Confirmation: FBLN1, NOTCH3, and CD34 effectively delineate stromal (fibroblasts, smooth muscle cells) and endothelial cell populations. The clear segregation of endothelial cells by CD34 expression is fundamental for analyzing vascular components and their potential roles in tumor angiogenesis or kidney disease.
  4. Annotation Quality: Overall, the chosen marker genes show highly specific expression patterns that align remarkably well with the celltype_minor annotations. This indicates a high quality of cell type assignment, suggesting that downstream differential expression, gene set enrichment, and cell-cell interaction analyses will be performed on well-defined cellular populations. The consistency between gene expression and cluster identity enhances confidence in the dataset's biological interpretation.

Annotation Notes

The strong concordance between canonical marker gene expression and the celltype_minor annotations across diverse cell lineages (immune, epithelial, stromal, endothelial) suggests a high quality and reliability of the cell type assignments in this AnnData object. The clear segregation of cell types on the UMAP, supported by distinct marker expression, indicates that the clustering and annotation processes have successfully captured the underlying biological heterogeneity. The presence of 'unassigned' cells is expected in complex tissues and may represent rare cell types, transitional states, or cells with ambiguous marker expression that require further investigation.

3. Celltype Subtype Marker Expression Analysis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of marker genes across different celltype_subset populations identified in the single-cell RNA-seq data from human kidney tissue. The plot is designed to visualize the specificity and mean expression level of selected surfaceome-enriched marker genes for each cell type, serving as a comprehensive overview and validation of the assigned cell identities. Each row represents a celltype_subset, and each column represents a marker gene. The size of the dot corresponds to the fraction of cells within that group expressing the gene, while the color intensity indicates the mean expression level of the gene in that group. Red boxes highlight the top markers identified for each respective cell type.

Visual Summary

The dot plot exhibits a generally well-defined diagonal pattern, indicating that most celltype_subset annotations are supported by distinct and highly expressed marker genes. This clear segregation of marker expression patterns for different cell types is crucial for robust cell type identification.

Biological Interpretation

The observed marker gene expression patterns largely confirm the assigned celltype_subset annotations, aligning with known biological identities in kidney tissue.

Immune Cell Lineages:

Stromal and Endothelial Cells:

Kidney-Specific Epithelial Cells:

Annotation Notes

While most celltype_subset populations exhibit clear and distinct marker profiles, one notable observation pertains to the annotation of Proximal Tubule cells:

  1. Contamination or misclassification: A portion of cells labeled as Proximal Convoluted Tubule S1_S2 might actually belong to the Thick Ascending Limb.
  2. Shared biological states: Less likely, given the distinct functions of these nephron segments, but possible if there's a transitional or stress-induced phenotype.
  3. Limitations of marker finding: The algorithm might have selected these markers if they were highly expressed in this group relative to many *other* groups, even if not exclusively expressed compared to TAL cells, or the rem_mkrs_common_in_N_groups_or_more parameter did not filter this specific overlap effectively.

Overall, the marker expression analysis provides strong support for the majority of celltype_subset annotations, while also highlighting a specific area for potential refinement within the kidney epithelial cell populations.

4. Genomic Copy Number Alterations in Tumor-Origin and Unassigned Kidney Cells

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) in specific cell populations ("Intercalated cell" and "unassigned" cells) from kidney tissue, grouped by sample. Intercalated cells are noted as a "Tumor origin celltype" in the data context. The goal is to identify recurrent genomic gains and losses using log2(CNR) (Copy Number Ratio) values, visualize these alterations across genomic regions, and summarize frequently altered cytogenetic bands to gain insight into the genomic instability characteristic of these cells.

Visual Summary

CNV Heatmap

The heatmap displays log2(CNR) values for individual cells (aggregated by sample) across genomic spots, ordered by chromosome.

Summary of Significant Amplified Regions

The summary heatmap and bar plot highlight frequently altered cytogenetic bands.

Key Amplified Bands:

Biological Interpretation

The analysis focuses on "Intercalated cell" and "unassigned" populations, with Intercalated cells identified as a "Tumor origin celltype" in kidney tissue. The observed extensive copy number amplifications and deletions in these specific cell populations have significant biological implications:

Clinical or Translational Implications

5. CNV-driven UMAP Embedding of Kidney Single-Cell RNA-seq Data

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes single-cell RNA-seq data from kidney tissue on a Uniform Manifold Approximation and Projection (UMAP) plot, where the embedding was specifically constructed using Copy Number Variation (CNV) estimates. This approach aims to cluster cells based on their genomic instability and chromosomal aberrations, which are hallmarks of cancer. The UMAP plots are colored by major cell type, minor cell type, inferred ploidy status, sample condition (tumor/normal), and individual sample identifiers to provide a comprehensive view of how these biological features relate to the CNV landscape.

Visual Summary

Cell Type Distribution and CNV

Biological Interpretation

The CNV-driven UMAP provides compelling evidence for distinct genomic profiles within the kidney single-cell landscape, strongly differentiating tumor from normal cells based on their copy number variations.

Annotation Notes

References

  1. Genomic Instability in Cancer: Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646-674. PubMed Search: "hallmarks of cancer genomic instability"
  2. Intercalated Cells in Renal Carcinoma: Cancer types arising from kidney collecting duct cells, including intercalated cells. PubMed Search: "intercalated cell renal cell carcinoma origin"

6. Kidney Cell Type Population Changes in Tumor vs. Normal Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis provides a stacked bar plot visualizing the relative proportions of minor cell types across individual samples, comparing normal kidney tissue with tumor tissue samples. This allows us to observe shifts in cellular composition associated with the disease state, offering insights into the tumor microenvironment and the impact of the tumor on normal tissue architecture.

Visual Summary

The stacked bar plot effectively highlights distinct cellular landscapes between normal and tumor kidney samples:

Biological Interpretation

The observed shifts in cell populations provide crucial biological insights into kidney cancer development and the resulting tumor microenvironment:

Clinical or Translational Implications

These findings have several potential clinical and translational implications for kidney cancer:

7. T 세포 하위 집단 분석: 신장 종양 미세환경 내 면역 세포 조성 변화

Report figure

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 사용하여 정상 신장 조직과 신장 종양 조직에서 T 세포 주요 집단(T cell major)에 속하는 다양한 면역 세포 하위 집단의 비율 변화를 시각화한 것입니다. celltype_major가 'T cell'인 세포들을 대상으로, celltype_subset 레벨에서 각 샘플별 구성 비율을 보여줍니다. 이에는 고전적인 T 세포 하위 유형뿐만 아니라 선천 림프구(ILC)와 자연 살해 세포(NK cell)도 포함됩니다.

Visual Summary

제공된 막대 그래프는 각 샘플에서 T 세포 주요 집단 내의 다양한 하위 유형의 상대적 비율을 시각화합니다. 그래프는 'normal'과 'tumor' 두 가지 조건으로 나뉘어 있습니다.

정상(normal) 신장 조직:

종양(tumor) 신장 조직:

Biological Interpretation

이 분석 결과는 신장 종양 미세환경(TME) 내 면역 세포 조성에 중요한 변화가 있음을 시사합니다.

Clinical or Translational Implications

이러한 면역 세포 조성의 변화는 신장암의 면역치료 전략 수립에 중요한 정보를 제공할 수 있습니다.

8. Macrophage Subset Population Analysis in Normal vs. Tumor Kidney Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional distribution of macrophage subsets (Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D)) within single-cell RNA-seq data from human kidney samples. The primary goal is to compare the macrophage polarization state between normal kidney tissue and kidney tumor tissue at the single-sample level, offering insights into the immunological landscape in the tumor microenvironment.

Visual Summary

The bar plots display the relative proportions of five macrophage subsets across individual normal (left panel) and tumor (right panel) kidney samples.

Normal Kidney Samples:

Kidney Tumor Samples:

Biological Interpretation

The observed shift in macrophage subset composition between normal and tumor kidney tissue highlights a differential immune response in the context of renal cell carcinoma.

Clinical or Translational Implications

The distinct macrophage polarization patterns observed in kidney tumors compared to normal tissue could have several clinical implications:

---

References:

  1. M1 Macrophage function: PubMed Search: M1 macrophage function cancer
  2. M2 Macrophage function in cancer: PubMed Search: M2 macrophage tumor progression
  3. Macrophages as prognostic markers in kidney cancer: PubMed Search: renal cell carcinoma macrophage prognosis
  4. Targeting macrophages in cancer therapy: PubMed Search: macrophage targeted therapy cancer

9. Changes in T Cell Subset Proportions in Kidney Tumor Microenvironment

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportions of T cell subset populations derived from single-cell RNA sequencing data of human kidney tissue, comparing 'normal' and 'tumor' conditions. The plot_box_for_celltype_population_with_signif_difference tool was used to identify and visualize statistically significant differences in cell type proportions between these conditions for T cell subsets. The analysis specifically focused on populations within the celltype_major: T cell category at the subset taxonomic level.

Visual Summary

The boxplots illustrate the relative proportions of two specific T cell subsets: Regulatory T cells (Treg) and Natural Killer (NK) cells, across 'normal' and 'tumor' conditions in kidney tissue.

Biological Interpretation

The observed shifts in Treg and NK cell proportions provide critical insights into the immune landscape of kidney tumors.

Together, these findings indicate a shift towards an immunosuppressive microenvironment in kidney tumors, characterized by an expansion of immune-suppressing Tregs and a depletion of anti-tumor NK cells. This imbalance creates an environment conducive to tumor growth and progression by dampening effective anti-tumor immune responses.

Clinical or Translational Implications

The significant changes in Treg and NK cell populations have substantial clinical and translational implications for kidney cancer:

References

  1. Treg cells in cancer:

PubMed search: "regulatory T cells cancer immunosuppression"

  1. NK cells in cancer:

PubMed search: "natural killer cells cancer immunity"

  1. Prognostic value of immune cells in kidney cancer:

PubMed search: "renal cell carcinoma NK Treg prognosis"

  1. NK cell-based therapies:

PubMed search: "NK cell therapy cancer"

10. Differential Macrophage Subset Proportions in Kidney Tumor vs. Normal Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional representation of specific macrophage subsets, namely Macrophage (M2C) and Macrophage (M2D), within kidney tissue, comparing tumor conditions against normal conditions. The goal is to identify macrophage populations that are significantly altered in abundance in the tumor microenvironment.

Visual Summary

The boxplots illustrate the celltype proportion of Macrophage (M2C) and Macrophage (M2D) in 'normal' versus 'tumor' kidney samples.

Overall, both M2C and M2D macrophage subsets appear to be more prevalent in the kidney tumor microenvironment than in healthy kidney tissue.

Biological Interpretation

Macrophages are a key component of the immune system and exhibit remarkable plasticity, polarizing into different functional states, often broadly categorized as M1 (pro-inflammatory, anti-tumor) and M2 (anti-inflammatory, pro-tumor) phenotypes. The observed increase in both Macrophage (M2C) and Macrophage (M2D) subsets in kidney tumor samples points towards a significant shift in macrophage polarization within the tumor microenvironment.

The enrichment of these pro-tumorigenic macrophage subsets in kidney tumors suggests that they likely play a critical role in the pathogenesis and progression of kidney cancer, potentially by dampening anti-tumor immunity and directly supporting cancer cell survival and spread. This aligns with the known immunosuppressive nature of the renal cell carcinoma (RCC) microenvironment.

Clinical or Translational Implications

The significant increase of M2C and the suggestive increase of M2D macrophages in kidney tumors hold important clinical implications:

  1. Biomarkers: The proportions of M2C and M2D macrophages could serve as potential biomarkers for kidney cancer progression or prognosis. Higher proportions might correlate with more aggressive disease or poorer patient outcomes.
  2. Therapeutic Targets: Modulating macrophage polarization or targeting specific M2 subsets represents a promising therapeutic strategy. Strategies aimed at depleting M2 macrophages, reprogramming them towards an M1-like phenotype, or inhibiting their pro-tumorigenic functions (e.g., via specific signaling pathways) could enhance anti-tumor immunity and improve responses to existing therapies in kidney cancer patients.
  3. Understanding Immunosuppression: These findings contribute to a deeper understanding of the immunosuppressive landscape within kidney tumors, highlighting specific cellular players that contribute to immune evasion. This knowledge is crucial for developing novel immunotherapeutic approaches.

11. Cell-Cell Interaction Patterns in the Kidney Tumor Microenvironment

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns within the kidney tumor microenvironment (TME) focusing on key immune and tumor-origin cell types: Aneuploid Intercalated Cells (representing tumor cells), Macrophages, and CD8+ T cells. The dot plot visualizes the top 80 most significant and strong ligand-receptor interactions occurring under tumor conditions, providing insights into the complex communication networks that drive tumor progression and immune modulation.

Visual Summary

The dot plot displays a matrix of cell-cell interactions (y-axis) against specific ligand-receptor pairs (x-axis) within the 'tumor' condition. The size of each dot correlates with the statistical significance of the interaction (-log10(p-value)), while its color represents the mean expression level of the interacting ligand-receptor pair (log2(mean)).

Key visual observations include:

Biological Interpretation

The observed cell-cell interactions shed light on critical biological processes likely active in the kidney tumor microenvironment:

Tumor-Macrophage Crosstalk as a Central Axis:

Macrophage Autocrine Regulation:

T Cell-Macrophage Communication:

T Cell Intrinsic Signaling:

Clinical or Translational Implications

The identified cell-cell interaction patterns offer several potential avenues for clinical and translational applications in kidney cancer:

Therapeutic Target Prioritization:

Biomarker Development:

Combination Therapies:

Immune Microenvironment Reprogramming:

12. Differential Cell-Cell Interaction Analysis in Normal vs. Tumor Kidney Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis comprehensively investigates cell-cell interaction (CCI) landscapes in normal and tumor kidney tissues using single-cell RNA sequencing data. By employing CellPhoneDB, significant ligand-receptor interactions between various cell types, including the ploidy-inferred Intercalated Cells, were identified and visualized. The primary objective is to delineate distinct communication patterns that characterize kidney homeostasis versus the tumor microenvironment, offering insights into disease mechanisms and potential therapeutic vulnerabilities. The analysis focuses on the top 80 most significant interactions (p-value < 0.05, mean expression > 0.01) for each condition.

Visual Summary

The provided dot plots clearly illustrate condition-specific cell-cell communication networks. Each plot displays cell-pair interactions on the y-axis and specific ligand-receptor pairs on the x-axis. The statistical significance of an interaction is conveyed by the size of the dot (-log10(p-value)), with larger dots indicating higher significance, while the color intensity represents the mean expression level (log2(mean)) of the interacting ligand-receptor pair, with brighter yellow/green indicating higher expression.

Key Observations for Normal Condition (Top Plot):

Key Observations for Tumor Condition (Bottom Plot):

Biological Interpretation

The comparative analysis reveals significant biological shifts in cell-cell communication within the kidney tumor microenvironment (TME) compared to normal tissue.

  1. Aneuploid Intercalated Cells as Drivers of Tumor Communication: The dramatic increase in interactions involving "Aneuploid IC" in the tumor context strongly implicates these cells as central players in shaping the TME. As the AnnData context suggests "Intercalated cell" as a "Tumor origin celltype" and "Aneuploid" as a ploidy status, these interactions likely represent communication orchestrated by malignant tumor cells.
  1. Extracellular Matrix (ECM) Remodeling for Tumor Progression:
  1. Modulation of the Immune Microenvironment:

Clinical or Translational Implications

The identified alterations in cell-cell communication within the kidney TME highlight several potential therapeutic targets and biomarker opportunities.

  1. Targeting Tumor Angiogenesis: The robust VEGFA-VEGFR signaling, particularly involving Aneuploid ICs and Endothelial cells, strongly supports the continued and potentially refined application of anti-angiogenic therapies (e.g., VEGFR inhibitors) in kidney cancer treatment. These data provide direct evidence of their biological rationale in this specific disease context.
  2. Interfering with ECM Remodeling and Adhesion:
  1. Immunomodulation:
  1. Biomarker Discovery: Specific ligand-receptor pairs that are uniquely upregulated or highly active in the tumor microenvironment, especially those involving Aneuploid Intercalated cells, could serve as valuable prognostic or predictive biomarkers. For instance, high levels of SPP1, VEGFA, or specific integrin chains could indicate disease progression, metastatic potential, or responsiveness to specific targeted therapies, aiding in personalized treatment strategies.

These findings provide a data-driven foundation for prioritizing molecular targets for further preclinical validation and inform the design of future clinical trials aimed at disrupting critical communication pathways in kidney cancer.

13. Immune Checkpoint and Cell Cycle Pathway Interactions in Kidney Tumor Microenvironment

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) mediated by a curated set of immune checkpoint and cell cycle-related genes in normal versus tumor kidney tissue. The plot_cci_dots tool was used to visualize significant ligand-receptor interactions between various cell types, with dot size representing the negative log10 of the p-value and dot color indicating the log2 of the mean expression of the ligand-receptor pair. The comparison focuses on differences in interaction patterns across conditions and the involvement of specific cell populations, including the identified tumor-originating aneuploid intercalated cells.

Visual Summary

Normal Kidney Tissue CCI (Top Plot)

The plot for normal kidney tissue reveals several significant cell-cell interactions involving Macrophages (Mac), Endothelial cells (Endo), and Diploid Intercalated cells (Diploid IC).

Key Interacting Pairs:

Tumor Kidney Tissue CCI (Bottom Plot)

The tumor kidney tissue plot displays a more complex and expanded network of interactions, involving T cell CD8+ (T CD8+), Smooth muscle cells (SMC), Macrophages (Mac), Endothelial cells (Endo), and notably, Aneuploid Intercalated cells (Aneuploid IC).

Immune-Related Interactions:

Biological Interpretation

  1. Tumor-Specific Intercalated Cell Dynamics: The stark contrast between "Diploid IC" in normal and "Aneuploid IC" in tumor is highly significant. The AnnData context indicates obs['ploidy_dec'] classifies cells as Aneuploid or Diploid, and 'Intercalated cell' is listed as a tumor_origin_celltype. This strongly suggests that the Aneuploid Intercalated cells in the tumor microenvironment (TME) represent the malignant cells or a highly dysplastic population. Their extensive engagement in CCIs, especially with immune and stromal components, highlights their central role in driving tumor progression.
  1. EGFR Signaling as a Key Driver in Tumor: In the tumor microenvironment, EGFR signaling, mediated by multiple ligands (AREG, EGF, EREG, HBEGF, TGFA), is highly active, particularly between Macrophages and Aneuploid Intercalated cells. EGFR activation promotes cell proliferation, survival, angiogenesis, and can contribute to immune evasion, making it a critical pathway for tumor growth and communication within the TME. The widespread and strong interactions involving EGFR suggest its central role in both tumor cell-intrinsic signaling and tumor-stroma communication.
  1. TGF-beta Pathway in Immunosuppression and Tumor Progression: TGF-beta signaling is consistently observed in both normal and tumor conditions. In the tumor setting, the continued presence of TGF-beta interactions, particularly involving Aneuploid Intercalated cells, Macrophages, and Endothelial cells, indicates its potential role in orchestrating an immunosuppressive microenvironment, promoting fibrosis, and supporting tumor growth and metastasis. The TGFB1-integrin_avb6_complex, notably present in endothelial cells, is known to activate latent TGF-beta, further reinforcing this role.
  1. T Cell Receptor Signaling in CD8+ T cells: The LCK-CD8_receptor interaction within CD8+ T cells (T CD8+|T CD8+) in the tumor environment is an important indicator of T cell activity. LCK is a crucial tyrosine kinase involved in initiating T cell receptor (TCR) signaling following antigen recognition. This self-interaction might reflect the presence of activated or recently activated CD8+ T cells within the tumor, which are essential for anti-tumor immunity. However, the exact functional state (e.g., cytotoxic vs. exhausted) requires further investigation.
  1. Macrophage-Tumor Cell Crosstalk: Macrophages exhibit extensive and strong interactions with Aneuploid Intercalated cells through various EGFR ligands and TGF-beta. Tumor-associated macrophages (TAMs) are known to play a dual role, often promoting tumor growth, angiogenesis, and immunosuppression through the secretion of growth factors and cytokines, including EGFR ligands. This intricate crosstalk highlights the macrophages' critical role in supporting tumor progression.

Clinical or Translational Implications

  1. Therapeutic Targeting of EGFR and TGF-beta Pathways: Given the strong and widespread activation of both EGFR and TGF-beta signaling pathways in the tumor, especially involving the presumed malignant Aneuploid Intercalated cells, these pathways represent compelling therapeutic targets in kidney cancer.
  1. Understanding Immune Evasion Mechanisms: The interplay between Aneuploid Intercalated cells, Macrophages, and Endothelial cells via these pathways provides insights into potential mechanisms of immune evasion in kidney cancer. For instance, TGF-beta is a potent immunosuppressant, and its active signaling could contribute to T cell dysfunction or exclusion from the TME.
  2. Biomarker Identification: The specific patterns of ligand-receptor interactions, particularly those amplified in the tumor and involving Aneuploid Intercalated cells, could serve as prognostic biomarkers for disease progression or predictive biomarkers for response to targeted therapies.
  3. Implications for Immunotherapy: While direct immune checkpoint (e.g., PD-1/PD-L1) interactions are not the most prominent in these specific plots, the presence of LCK-CD8 signaling and IFNG interactions within the TME suggests an active immune context. Understanding how the identified EGFR and TGF-beta pathways modulate the efficacy of existing immunotherapies, such as anti-PD-1/PD-L1 antibodies, would be a critical area for further research and clinical investigation. For example, TGF-beta signaling can lead to resistance to immune checkpoint blockade.

14. Condition-Specific Cell-Cell Interaction Patterns in Kidney Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates statistically significant differences in cell-cell interactions (CCIs) between normal and tumor kidney tissue. The plot_dot_for_cci_with_signif_difference tool was used to identify and visualize CCIs that are significantly elevated in one condition compared to the other. The focus was on major immune and stromal cell types, including Myeloid cells, T cells, Mast cells, B cells, Endothelial cells, and Stromal cells. Up to 25 top significant CCIs were selected for each condition, based on their p-values, highlighting distinct communication landscapes associated with disease status.

Visual Summary

The dot plot effectively illustrates condition-specific CCI patterns across individual samples. Each row represents a sample, grouped by 'normal' or 'tumor' conditions, while each column corresponds to a specific ligand-receptor interaction between two cell types (CCI index).

Key Observations:

Biological Interpretation

The observed condition-specific CCI patterns underscore profound biological shifts in the kidney microenvironment during tumorigenesis.

Normal Tissue Homeostasis and Immune Surveillance

Tumor Microenvironment Remodeling and Pro-tumorigenic Signaling

Clinical or Translational Implications

The distinct CCI patterns identified have several potential clinical and translational implications:

15. Condition-Specific Surfaceome Markers of Intercalated Cells in Kidney Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers that distinguish Intercalated cells under different conditions (normal vs. tumor) and ploidy states (Diploid vs. non-Diploid/Aneuploid) within the kidney. Given that Intercalated cells are noted as a potential "tumor origin celltype" in the AnnData context, understanding their specific markers in tumor settings is crucial for comprehending renal carcinogenesis and identifying therapeutic opportunities. The dot plot visualizes the mean expression and percentage of cells expressing up to 50 surfaceome markers for Intercalated cells, grouped by inferred ploidy status and sample condition (normal or tumor).

Visual Summary

The dot plot effectively illustrates distinct patterns of surfaceome marker expression across Intercalated cell populations:

Biological Interpretation

The observed differential expression of surfaceome markers in Intercalated cells provides significant biological insights:

Clinical or Translational Implications

The identification of condition-specific surfaceome markers for Intercalated cells holds significant clinical and translational potential, especially given their implied role as a tumor-origin cell type in renal cancer:

16. Macrophage Condition-Specific Surfaceome Markers in Kidney Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify condition-specific surfaceome markers within the Macrophage cell population in kidney tissue, comparing 'tumor' versus 'normal' conditions. The plot_markers_and_expression_dot tool was used to visualize the expression of up to 50 surfaceome markers per condition for Macrophages, enabling the identification of potential biomarkers and therapeutic targets.

Visual Summary

The dot plot visualizes the expression of various surfaceome genes across different samples within the Macrophage cell type.

Key Observations:

Biological Interpretation

This analysis successfully identifies a distinct surfaceome signature for Macrophages residing in the kidney tumor microenvironment compared to non-tumor or normal conditions. The robust upregulation of numerous surface markers in 'tumor' samples suggests a highly activated and functionally distinct state for these tumor-associated macrophages (TAMs).

The distinct surfaceome profile suggests that kidney tumor-associated macrophages adopt a specialized phenotype, likely geared towards supporting tumor growth, immune evasion, and tissue remodeling.

Clinical or Translational Implications

The identified condition-specific surfaceome markers on Macrophages hold significant clinical and translational potential, particularly in the context of kidney cancer:

17. T cell CD4+ Condition-Specific Surfaceome Markers in Kidney Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers that distinguish CD4+ T cells between normal and tumor conditions within kidney tissue. Using single-cell RNA sequencing data, the plot_markers_and_expression_dot tool generated a dot plot visualizing the mean expression level and the fraction of cells expressing these surface markers for CD4+ T cells across two samples (SI_22369, SI_22368) and two conditions (normal, tumor). The analysis focused on finding up to 50 surfaceome markers per condition.

Visual Summary

The dot plot displays surfaceome gene expression for CD4+ T cells. The size of each dot represents the fraction of cells expressing a gene, and the color intensity indicates the mean expression level within that cell group.

Condition-Specific Patterns:

Biological Interpretation

The observed gene expression profile for CD4+ T cells within the tumor microenvironment of sample SI_22368 suggests an activated, highly interactive, and potentially migratory phenotype.

  1. Antigen Presentation and Immune Activation: The strong upregulation of MHC Class II genes (HLA-DRA, HLA-DRB1, HLA-DPB1, HLA-DPA1) and CD74 (MHC II invariant chain) on CD4+ T cells within the tumor is notable. While typically expressed by professional antigen-presenting cells (APCs), CD4+ T cells themselves can express MHC Class II upon activation, suggesting these T cells might be directly involved in antigen presentation, possibly influencing other immune cells or modulating their own responses within the tumor [PMID: 15574340].
  2. Cell Adhesion and Trafficking: Elevated expression of integrins (ITGA4, ITGB2) and adhesion molecules (ICAM3) indicates active cell-cell interactions and potential trafficking capabilities. ITGA4 (CD49d) forms VLA-4, important for lymphocyte migration to inflamed tissues, while ITGB2 (CD18) forms part of LFA-1 and Mac-1, critical for extravasation and immune synapse formation [GeneCards: ITGA4, ITGB2]. S1PR4 is involved in lymphocyte egress and localization, suggesting modulated movement within the tumor.
  3. T Cell Activation and Co-stimulation: The presence of CD3G confirms their T cell identity and signaling potential. Markers like CD27 (a TNF receptor superfamily member crucial for T cell activation and memory) and TNFRSF14 (HVEM, a co-stimulatory/co-inhibitory receptor) suggest these CD4+ T cells are actively engaged in costimulatory signaling pathways, influencing their activation, survival, and differentiation states within the tumor microenvironment [GeneCards: CD27, TNFRSF14].
  4. Specific T Cell Subsets/Functions: KLRB1 (CD161) is expressed on specific T cell subsets, including NK-like T cells or some Th17 cells, suggesting the presence of these particular populations adapting to the tumor context. BSG (CD147) can promote tumor progression and angiogenesis by inducing metalloproteinases; its expression on immune cells may indicate an adaptive role in the tumor microenvironment, possibly mediating interactions with tumor cells.
  5. Regulation and Signaling: PIK3IP1 can negatively regulate PI3K signaling, a critical pathway for T cell activation and survival, suggesting potential feedback or modulatory mechanisms at play.

Collectively, these findings portray a CD4+ T cell population in the tumor microenvironment (specifically in SI_22368) that is highly responsive, adhesive, and engaged in complex immune interactions. This extensive surfaceome signature could reflect various functional states, including conventional effector T cells, regulatory T cells, or exhausted T cells, all adapting to the unique demands of the tumor.

Clinical or Translational Implications

The identified condition-specific surfaceome markers have several potential clinical and translational implications:

18. Gene Ontology (GSA) Analysis of Intercalated Cells in Kidney Tissue

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results for Intercalated cells derived from single-cell RNA-seq data of kidney tissue. The GSA was performed to identify pathways significantly upregulated under different conditions:

  1. Diploid vs. Others: Comparing Diploid Intercalated cells against other Intercalated cells (presumably Aneuploid, based on ploidy_dec annotation).
  2. Normal vs. Others: Comparing Intercalated cells from normal kidney tissue against those from other conditions (presumably tumor tissue).
  3. Tumor vs. Others: Comparing Intercalated cells from tumor kidney tissue against those from other conditions (presumably normal tissue).

The results are visualized as bar plots, with bar length representing the negative logarithm of the p-value and FDR-corrected q-value, indicating the statistical significance of pathway enrichment. Higher values (-log) denote greater significance.

Visual Summary

The bar plots display the top enriched GO terms (pathways) for Intercalated cells under each comparison condition.

Biological Interpretation

The distinct GO term enrichments highlight significant functional shifts in Intercalated cells based on tissue condition (normal vs. tumor) and ploidy status.

Clinical or Translational Implications

19. Intercalated cell, Macrophage, and T cell CD4+ Gene Set Enrichment Analysis in Kidney Tumor Microenvironment

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results for three key kidney cell types: Intercalated cells, Macrophages, and CD4+ T cells. The GSEA compares distinct cellular states or conditions for each cell type:

  1. Intercalated cells:
  1. Macrophages:
  1. T cell CD4+:

The dot plot visualizes the Normalized Enrichment Score (NES) using a RdBu_r colormap (red indicates positive enrichment/upregulation, blue indicates negative enrichment/downregulation) and the significance (-log(p-value)) through dot size (larger dots indicating higher significance).

Visual Summary

The dot plot effectively highlights significantly enriched or depleted pathways across different cell types and conditions. Key patterns observed include:

Biological Interpretation

Intercalated Cells (Tumor Origin Celltype)

Given that Intercalated cells are identified as a "Tumor origin celltype" in the data context, their GSEA results are particularly critical for understanding tumor initiation and progression.

Diploid vs. Aneuploid Intercalated Cells:

Tumor vs. Normal Intercalated Cells:

Macrophages

Macrophages in the tumor microenvironment (Tumor-Associated Macrophages, TAMs) are known to adopt diverse functional states, often promoting tumor growth and immune suppression.

Tumor vs. Normal Macrophages:

T cell CD4+

CD4+ T cells play a critical role in orchestrating anti-tumor immunity, but can become dysfunctional in the tumor microenvironment.

Tumor vs. Normal CD4+ T Cells:

Tumor CD4+ T cells show hallmarks of immune dysfunction and exhaustion

Clinical or Translational Implications

The GSEA results provide crucial insights into the mechanisms driving kidney tumor progression and immune evasion:

  1. Intercalated cells as a Therapeutic Target: The significant upregulation of oncogenic pathways (PI3K-Akt, MAPK, ErbB, VEGF) and immune checkpoint molecules (PD-L1) in tumor-derived intercalated cells (identified as a tumor origin celltype) suggests these pathways are potential therapeutic targets. Targeting these pathways directly in tumor cells could inhibit proliferation and enhance anti-tumor immunity [PubMed Search: PI3K-AKT pathway cancer therapy; PubMed Search: PD-L1 expression tumor cells].
  2. Reprogramming TAMs: The observed shift in macrophage phenotype away from pro-inflammatory and phagocytic functions in the tumor microenvironment highlights the need for strategies to reprogram TAMs towards an anti-tumorigenic state. Restoring phagocytic capacity or reactivating TNF signaling in TAMs could be beneficial. The lower PD-L1 expression in tumor macrophages (compared to normal) suggests that, in this context, targeting PD-L1 might be more effective on tumor cells or T cells than on TAMs, or that specific TAM subsets might have divergent PD-L1 expression.
  3. Combating T Cell Exhaustion: The clear evidence of T cell exhaustion in CD4+ T cells (downregulated TCR signaling, upregulated PD-1/PD-L1 pathway) underscores the importance of immune checkpoint blockade therapies. Combining PD-1/PD-L1 inhibition with strategies to reinvigorate T cell receptor signaling or overcome T cell anergy could be critical for effective immunotherapy in kidney cancer patients. [PubMed Search: T cell exhaustion cancer therapy]
  4. Ploidy as a Biomarker: The distinct pathway enrichment in diploid versus aneuploid intercalated cells suggests that ploidy status could serve as a biomarker for disease progression or responsiveness to specific therapies. Further investigation into the functional differences between these ploidy states could reveal novel therapeutic avenues.

20. Discussion

The comprehensive single-cell analysis of kidney tissue elucidates striking cellular and molecular reprogramming in kidney cancer compared to normal tissue, confirming the dataset's capacity to reveal disease-specific biological insights. A central finding is the malignant transformation of Intercalated cells, explicitly noted as a tumor-origin cell type in the data context. These cells exhibit widespread aneuploidy and recurrent genomic amplifications, notably of EGFR on chromosome 7, which is a well-known oncogene (Section 4, 5). Transcriptomically, tumor-associated Intercalated cells actively upregulate oncogenic pathways, including PI3K-Akt, MAPK, ErbB, and VEGF signaling, crucial for proliferation, survival, and angiogenesis (Section 19). Furthermore, they express immune checkpoint molecules like PD-L1, CXCR4, CD70, and VCAM1, suggesting their direct involvement in immune evasion and metastatic potential (Section 15, 19). GSA results further show these cells activate HIF-1 signaling, pathways in cancer, and demonstrate altered protein processing, indicating adaptation to the hypoxic and stressful TME (Section 18). In contrast, normal Intercalated cells maintain a distinct metabolic signature dominated by oxidative phosphorylation, reflecting their physiological roles (Section 18).

The tumor microenvironment (TME) is characterized by a dynamic and often paradoxical immune landscape. While population analysis reveals a relative increase in overall immune cells, detailed subtyping uncovers significant shifts towards immunosuppression. We observe a significant expansion of regulatory T cells (Tregs) and a marked decrease in natural killer (NK) cells in the tumor condition compared to normal, indicating a compromised anti-tumor immune response (Section 9). Macrophage polarization also shifts: while M1 (pro-inflammatory) macrophages are prominent, there is also a significant enrichment of pro-tumorigenic M2C and a trend towards increased M2D macrophage subsets in tumors (Section 8, 10). GSEA confirms that tumor macrophages downregulate classical immune activation pathways like Fc gamma R-mediated phagocytosis and TNF signaling, suggesting a shift away from robust anti-tumorigenic functions (Section 19). CD4+ T cells in the tumor microenvironment show clear signs of exhaustion, with downregulation of T cell receptor signaling and upregulation of the PD-1 checkpoint pathway, highlighting a critical mechanism of immune evasion (Section 19).

Cell-cell interaction analyses further reveal the intricate communication networks orchestrating tumor progression. EGFR ligands (AREG, EREG, HBEGF) interacting with EGFR, as well as VEGFA/PGF with NRP1/VEGFR, are highly active between aneuploid Intercalated cells, macrophages, and endothelial cells, driving tumor cell proliferation and robust angiogenesis (Section 11, 12, 13, 14). The SPP1-integrin axis is notably upregulated in tumor interactions, mediating ECM remodeling, invasion, and immune modulation (Section 11, 12). Chemokine signaling via CXCL12-CXCR4 is prominent, facilitating immune cell recruitment and tumor cell migration (Section 11, 12). These interactions create a self-sustaining pro-tumorigenic environment, enabling malignant Intercalated cells to evade immune surveillance, proliferate, and metastasize.

Hypotheses:

  1. Malignant transformation of Intercalated cells is driven by recurrent EGFR amplification and activation of PI3K-Akt, MAPK, ErbB, and VEGF signaling pathways, leading to their proliferation and survival in kidney cancer.
  2. The kidney tumor microenvironment actively suppresses anti-tumor immunity by expanding regulatory T cells and pro-tumorigenic M2C/M2D macrophages, while simultaneously inducing exhaustion in CD4+ T cells and depleting NK cell populations.
  3. Cell-cell interactions involving EGFR, VEGFA-VEGFR, SPP1-integrin, and CXCL12-CXCR4 pathways between tumor-origin Intercalated cells, macrophages, and endothelial cells are critical mediators of angiogenesis, ECM remodeling, and immune evasion in kidney cancer.
  4. The observed aneuploidy in Intercalated cells is a key genomic alteration linked to their malignant phenotype and correlates with activation of specific oncogenic and stress response pathways.

Potential therapeutic targets:

  1. EGFR: EGFR is recurrently amplified in tumor-origin Intercalated cells and its signaling pathway (ErbB) is highly upregulated, driving cell proliferation, survival, and angiogenesis. It is also involved in extensive tumor-macrophage and macrophage-macrophage crosstalk. Evidence: Recurrent EGFR amplification on chromosome 7 (Section 4). Upregulation of 'ErbB signaling pathway' and 'PI3K-Akt signaling pathway' in tumor Intercalated cells (GSEA, Section 19). Strong EGFR-mediated CCIs (AREG/EREG/HBEGF-EGFR) between tumor cells and macrophages (CCI, Section 11, 13). Upregulation of EGFR as a surfaceome marker on tumor Intercalated cells (Section 15). Validation: Test EGFR tyrosine kinase inhibitors or anti-EGFR monoclonal antibodies in patient-derived organoids or xenograft models of kidney cancer. Assess effects on tumor growth, proliferation, and downstream signaling. Conduct clinical trials for patients with EGFR-amplified kidney cancer.
  2. VEGFA/VEGFR Pathway: The VEGFA signaling pathway is significantly activated in tumor Intercalated cells and plays a critical role in promoting angiogenesis, which is essential for tumor growth and metastasis. Evidence: Upregulation of 'VEGF signaling pathway' in tumor Intercalated cells (GSEA, Section 19). Robust VEGFA-VEGFR1/VEGFR2 interactions, particularly between aneuploid Intercalated cells and endothelial cells in tumor conditions (CCI, Section 11, 12, 14). Validation: Evaluate the efficacy of anti-VEGF/VEGFR agents (e.g., bevacizumab, sunitinib, pazopanib) in preclinical models. Monitor vascular density and tumor growth. Analyze patient response to existing anti-angiogenic therapies in the context of these findings.
  3. SPP1-Integrin Axis: SPP1-integrin interactions are highly upregulated in the tumor microenvironment, mediating extracellular matrix remodeling, tumor cell invasion, metastasis, and immune modulation. Evidence: Significant upregulation of SPP1-integrin signaling across multiple tumor-associated cell interactions (e.g., SMC/SMC, Mac/T cell CD8+, Aneuploid IC interactions) in tumor conditions (CCI, Section 11, 12). Validation: Test SPP1-blocking antibodies or integrin antagonists (e.g., targeting alpha-v integrins) in *in vitro* invasion/migration assays and *in vivo* metastasis models. Assess effects on tumor progression and TME composition.
  4. Regulatory T cells (Tregs): Tregs are significantly expanded in the kidney tumor microenvironment, contributing to immunosuppression and allowing tumor progression. Evidence: Significantly higher proportion of Treg cells in tumor conditions (boxplot, p ≤ 0.05, Section 9). Validation: Explore strategies for Treg depletion (e.g., anti-CTLA-4 antibodies) or functional inhibition in preclinical kidney cancer models. Evaluate their impact on anti-tumor immune responses and tumor growth, potentially in combination with other immunotherapies.
  5. CXCR4: CXCR4 signaling is prominent in the tumor microenvironment, mediating tumor cell migration, invasion, and recruitment of immune cells, contributing to an immunosuppressive environment. Evidence: CXCL12-CXCR4 and CXCL14-CXCR4 axes are prominent in tumor-macrophage and macrophage-T cell interactions (CCI, Section 11). CXCR4 is upregulated as a surfaceome marker on tumor Intercalated cells (Section 15). Validation: Test CXCR4 antagonists in preclinical models to assess effects on tumor cell migration, metastasis, and immune cell infiltration into the TME. Combine with immunotherapies to evaluate synergistic effects.
  6. Macrophage (M2C/M2D) Polarization: M2C and M2D macrophages are significantly enriched in the tumor microenvironment and are associated with promoting tumor growth, angiogenesis, and immune suppression. Evidence: Significant elevation of M2C macrophages in tumor tissue (boxplot, p ≤ 0.05, Section 10). Trend towards increased M2D macrophages in tumor tissue (boxplot, p = 0.09, Section 10). Downregulation of 'Fc gamma R-mediated phagocytosis' and 'TNF signaling pathway' in tumor macrophages (GSEA, Section 19). Upregulation of pro-tumorigenic surfaceome markers like CSF1R, AXL, BSG, GPNMB in tumor macrophages (Section 16). Validation: Investigate CSF1R inhibitors to deplete or reprogram TAMs in preclinical models. Develop strategies to re-educate M2-like macrophages towards an M1-like phenotype using immunomodulatory agents. Assess changes in tumor growth and immune infiltration.

Follow-up validation ideas:

  1. Develop *in vitro* models (e.g., organoids, 3D co-cultures) using Intercalated cells to mimic tumor conditions and validate the impact of EGFR amplification/activation on cell proliferation, survival, and signaling pathways. Perturb these pathways using inhibitors or genetic knockdowns.
  2. Utilize patient-derived xenograft (PDX) or genetically engineered mouse models (GEMMs) of kidney cancer to *in vivo* validate the tumor-promoting roles of Intercalated cells and specific oncogenic pathways. Assess tumor growth, metastasis, and response to targeted therapies.
  3. Perform functional assays (e.g., cytotoxicity assays, T cell proliferation, cytokine secretion, phagocytosis) on isolated T cell subsets, NK cells, and macrophages from tumor and normal kidney samples to confirm their altered functional states.
  4. Employ spatial transcriptomics or proteomics on kidney tumor tissues to validate the localized expression of key surface markers (e.g., PD-L1, HLA Class II, CXCR4) and ligand-receptor interactions *in situ*, confirming their cellular source and spatial relationships.
  5. Conduct perturbation experiments *in vivo* (e.g., using blocking antibodies or small molecule inhibitors) targeting key cell-cell interaction pathways (EGFR, VEGFA-VEGFR, SPP1-integrin, CXCL12-CXCR4) to assess their impact on tumor growth, angiogenesis, metastasis, and immune modulation in preclinical models.
  6. Generate single-cell multi-omics data (e.g., scRNA-seq + scATAC-seq) from Intercalated cells across different ploidy states to identify epigenetic and transcriptional changes associated with aneuploidy and malignant transformation.
  7. Validate prognostic and predictive biomarkers identified (e.g., EGFR amplification, PD-L1 expression, NK:Treg ratio) in larger patient cohorts using immunohistochemistry or flow cytometry on clinical samples and correlate with patient outcomes and treatment responses.

Limitations:

The current analysis, while extensive, has certain limitations. Copy number variations are inferred from RNA-seq data, which provides an estimate rather than direct genomic sequencing and may miss subtle or localized CNVs. The single-cell RNA-seq data offers snapshot views, and longitudinal studies would be required to fully understand dynamic changes over disease progression. While cell-cell interaction models infer potential communication, functional validation through *in vitro* or *in vivo* perturbation experiments is necessary to confirm their biological impact. The 'unassigned' cell population, particularly prominent in tumor samples and overlapping with aneuploid cells, requires further in-depth characterization to fully ascertain their identity and malignant status. The observed associations between molecular pathways, cell types, and disease conditions are correlative and require experimental validation to establish causality for therapeutic targeting. Finally, the analysis is based on a limited number of samples, and results should be validated in larger and more diverse patient cohorts.

21. Query List

  1. Show UMAPs including condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns and save.
  2. Show expression of CD3D CD4 CD8A CD79A MS4A1 MZB1 CD14 LYZ FBLN1 NOTCH3 EPCAM MUC1 CD34 genes on UMAP along with minor cell type annotation. Set ncols=4 and save.
  3. Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
  4. Select tumor-origin cells and unassigned cells, group by sample, show CNV heatmap, and include a summary of significantly amplified regions and save.
  5. Show CNV patterns on UMAP. Include major cell type, minor cell type, ploidy results, condition, and sample in 2 columns and save.
  6. Show population bar plot of minor cell types and save.
  7. Show subset population barplot for T cells and save.
  8. Show subset population barplot for macrophages and save.
  9. Show boxplot for T cell subset populations if there are statistically significant differences between conditions and save. Set ncols appropriately considering the total number of panels.
  10. Show boxplot for macrophage subset populations if there are statistically significant differences between conditions and save. Set ncols appropriately considering the total number of panels.
  11. Show cell-cell interaction patterns by condition including tumor-origin cells, fibroblasts, macrophages, and T cells and save. Select a maximum of 80 cell-cell interactions per condition.
  12. Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
  13. Select only genes related to immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save.
  14. Find statistically significant differences in cell-cell interactions between conditions for major immune and stromal cells, show them as a dot plot, and save. Set max_n_items_per_group = 25.
  15. Show the condition-specific markers for tumor-origin cells (Intercalated cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
  16. Extract condition-specific markers for Macrophage, show as a dotplot, and save. Show only surfaceome markers, up to 50 per condition.
  17. Extract condition-specific markers for T cell CD4+, show as a dotplot, and save. Show only surfaceome markers, up to 50 per condition.
  18. Show Gene ontology (GSA) analysis results as a bar-plot for Intercalated cell and save.
  19. Show Gene set enrichment analysis results as a dotplot for Intercalated cell, Macrophage, and T cell CD4+ and save. Set color map to RdBu_r and n_pws_to_show = 80.
↑ Top